Predicting diet regimen adherence by ills with diabetes of type 1 - relationship with health locus of control

WSTĘP. Celem badań przedstawionych w niniejszej pracy była analiza związku między wymiarami umiejscowienia kontroli zdrowia: wewnętrznym i zewnętrznym a stężeniem hemoglobiny glikowanej HbA1c odzwierciedlającym wyrównanie metaboliczne u chorych na cukrzycę typu 1. Hemoglobinę glikowaną można także traktować jako biologiczny wskaźnik stosowania się do wymagań dietetycznych. MATERIAŁ I METODY. W stosunku do 62 chorych na cukrzycę typu 1 zastosowano Wielowymiarową Skalę Umiejscowienia Kontroli Zdrowia (MHLC-B) i ankietę osobową. WYNIKI. Uzyskane rezultaty wykazują, że u chorych na cukrzycę typu 1 średnia wartość wskaźnika HbA1c utrzymuje się powyżej normy. Istnieje związek między stężeniem hemoglobiny glikowanej a przekonaniami o zewnętrznym - w innych osobach lub w przypadku - umiejscowieniu kontroli zdrowia. Wyższe stężenie HbA1c mają osoby bez powikłań i z nowo rozpoznaną chorobą. WNIOSKI. Umiejscowienie kontroli zdrowia może być dodatkowym elementem, ważnym w psychoedukacji pacjentów, a służącym do przewidywania stosowania się przez chorych na cukrzycę typu 1 do zaleceń dietetycznych.BACKGROUND. Aim of the presents research was a study the interactions between dimensions of health locus of control: internal and external, with a level of glycosylated hemoglobin HbA1c, which reflected metabolic balance individuals with type 1 diabetes. So, it is possible to treat HbA1c as a biological coefficient of adherence to diet demands. MATERIAL AND METHODS. Sixty two patients with type 1 diabetes were administered and expanded Multidimensional Health Locus of Control - MHLC-B and a personal survey. RESULTS. Obtained results show that type 1 diabetics have HbA1c over norm. There is correlation between a level of glycosylated hemoglobin and external health of control beliefs - in others or in chance. Persons with a higher level of HbA1c have no complication with ill or they are new diagnosed diabetic. CONCLUSION. Health locus of control can be an additional component, important in psychoeducation of diabetics, and instrumental in prediction of adherence to diet by people with diabetes type 1

Dyspozycyjny optymizm a akceptacja choroby w grupie osób z chorobą Gravesa-Basedowa

Introduction: Dispositional optimism is a general tendency to positively perceive the world and one’s own future. We can consider what kind of connection with ability to cope with difficulties. One situation which is very stressful for an individual is an illness, particularly a chronic one. The aim of the paper was to define the connection between dispositional optimism and acceptance of illness among the group with Graves-Basedow disease. This is autoimmunizational illness and diseases of this kind are particularly sensitive to the influence of psychological factors, as there are many connections between the immune system and the human psyche. Material and methods: The study group consisted of 59 individuals with Graves-Basedow disease, 50 women and 9 men and 55 of healthy ones, 49 women and 6 men according to age, sex and a level of education. The patients filled out three psychological questionnaires: The Life Orientation Test-Revised (LOT-R), The Acceptance of Illness Scale (AIS) and The Personal Questionnaire. Results: of the study in question indicate a lack of differences between individuals with Graves-Basedow disease and healthy ones concerning the level of dispositional optimism. There no differences in the level of dispositional optimism as regards of criterions of health: by the levels of hormones TSH, fT3 and fT4, complications and a time of duration of disease. Instead, if they suffer additionally from others diseases, they have a lower level of dispositional optimism. There exist a connection between intensification of level of dispositional optimism and acceptance of illness among testing group. Conclusions: The dispositional optimism as a supply of individual helps her or his in adaptation to difficulty situation, which is a chronic disease. It is a reason way it is worth to help of patients to grow it stronger. Pol J Endocrinol 2008; 59 (1): 23-28Wstęp: Dyspozycyjny optymizm określa tendencję osoby do pozytywnej percepcji świata i własnej przyszłości. Można rozważać, jaki jest jego związek z umiejętnościami radzenia sobie z trudnościami. Jedną z takich trudnych sytuacji dla jednostki jest choroba, zwłaszcza choroba przewlekła. Celem niniejszej pracy było określenie związku między dyspozycyjnym optymizmem a akceptacją choroby w grupie osób z chorobą Gravesa-Basedowa. Jest to choroba autoimmunologiczną, a w tego typu chorobach, ze względu na liczne powiązania układu odpornościowego z ludzką psychiką, występuje szczególny rodzaj wrażliwości na czynniki psychologiczne. Materiał i metody: Grupa badana składała się z 59 osób z chorobą Gravesa-Basedowa - 50 kobiet i 9 mężczyzn oraz 55 osób zdrowych - 49 kobiet i 6 mężczyzn, które dobrano pod względem wieku, płci i wykształcenia w stosunku do osób chorych. Badane osoby wypełniły 3 kwestionariusze: Test Orientacji Życiowej (LOT-R, Life Orientation Test-Revised), Skalę Akceptacji Choroby (AIS, Acceptance of Illness Scale) i ankietę osobową. Wyniki: Wskazują one na brak różnic między osobami chorymi a zdrowymi w poziomie dyspozycyjnego optymizmu. Nie ma także różnic w zakresie poziomu dyspozycyjnego optymizmu ze względu na kryterium zdrowia, jakimi są: stężenie hormonów tarczycowych (TSH, fT3 i fT4), istnienie powikłań oraz czas chorowania. Natomiast osoby cierpiące dodatkowo z powodu innych schorzeń, miały istotnie niższy poziom dyspozycyjnego optymizmu od tych, które doświadczały tylko choroby Gravesa-Basedowa. Istnieje związek między nasileniem poziomu dyspozycyjnego optymizmu a akceptacją choroby w badanej grupie pacjentów. Wnioski: Dyspozycyjny optymizm jako zasób jednostki pomaga jej w adaptacji do tak trudnej sytuacji, jaką jest przewlekła choroba, dlatego warto pomagać pacjentom go wzmacniać. Endokrynol Pol 2008; 59 (1): 23-2

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from

Aim of the study: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland. Material and methods: A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013. Results: 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage - 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/ year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/ patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/pa tient/ year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/ year). There were 0.43 hospitalizations/ patient/year. For direct medical costs estimated at PLN 50 692/pa tient/ year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care - 49%, hospitalization - 23%, diagnostics/laboratory tests - 28%). Conclusions: These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study

AIM OF THE STUDY: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland. MATERIAL AND METHODS: A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013. RESULTS: 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage – 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/patient/year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/year). There were 0.43 hospitalizations/patient/year. For direct medical costs estimated at PLN 50 692/patient/year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care – 49%, hospitalization – 23%, diagnostics/laboratory tests – 28%). CONCLUSIONS: These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden